Antimicrobial susceptibility and macrolide resistance genes in Streptococcus pyogenes collected in Austria and Hungary

International Journal of Antimicrobial Agents

Volumn 24, Issue 3, 2004, Pages 290-293

  Gattringer, Rainer ^a   Sauermann, Robert ^a,b   Lagler, Heimo ^a   Stich, Karin ^a   Buxbaum, Astrid ^a   Graninger, Wolfgang ^a   Georgopoulos, Apostolos ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Austria; Hungary; Macrolide resistance; Streptococcus pyogenes; Susceptibility

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; JOSAMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; PENICILLIN G; TETRACYCLINE; VANCOMYCIN; BACTERIAL PROTEIN; BETA LACTAM; MEFA PROTEIN, STREPTOCOCCUS; MEMBRANE PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG SENSITIVITY; HUNGARY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES; DRUG EFFECT; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHARYNGITIS; PHARYNX; SKIN; STREPTOCOCCUS INFECTION; TONSILLITIS; VAGINA;

ANTI-BACTERIAL AGENTS; AUSTRIA; AZITHROMYCIN; BACTERIAL PROTEINS; BETA-LACTAMS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FEMALE; HUMANS; HUNGARY; JOSAMYCIN; MACROLIDES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; PHARYNGITIS; PHARYNX; SKIN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TETRACYCLINE RESISTANCE; TONSILLITIS; VAGINA;

EID: 4344705057     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.01.009     Document Type: Article

References (23)

1. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:2000;470-511
2. Jones R.N. The impact of antimicrobial resistance: changing epidemiology of community acquired respiratory-tract infections. Am. J. Health Syst. Pharm. 56:1999;S4-S11
3. Macris M.H., Hartman N., Murray B., et al. Studies of the continuing susceptibility of group A streptococcal strains to penicillin during eight decades. Pediatr. Infect. Dis. J. 17:1998;377-381
4. Esposito S., Noviello S., Ianniello F., et al. Short-course therapy with cefaclor for treatment of streptococcal pharyngotonsillitis. Int. J. Antimicrob. Agents. 18:2001;341-345
5. Feder H.M., Gerber M.A., Randolph M.F., et al. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics. 103:1999;47-51
6. Kaplan E.L., Gooch W.M., Notario G.F., et al. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). Clin. Infect. Dis. 32:2001;1798-1802
7. Seppälä H., Nissinen A., Jarvinen H., et al. Resistance to erythromycin in group A streptococci. N. Engl. J. Med. 326:1992;292-297
8. Giovanetti E., Montanari M.P., Mingoia M., et al. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob. Agents Chemother. 43:1999;1935-1940
9. Roberts M.C., Sutcliffe J., Courvalin P., et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43:1999;2823-2830
10. Farrell D.J., Morrissey I., Bakker S., et al. Molecular characterisation of macrolide resistance mechanism among Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J. Antimicrob. Chemother. 50:2002;39-47
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved Standard M7-A5. Wayne, PA, USA: NCCLS; 2000.
12. Comité de l' Antibiogramme de la Societé Francaise de Microbiologie. Statement 1996 CA-MSF. Zone sizes and breakpoints for non-fastidious organisms. Clin Microbiol Infect 1996;2(Suppl 1): S46-9.
13. Bingen E., Fitoussi F., Doit C., et al. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob. Agents Chemother. 44:2000;1453-1457
14. Milch H., Paszti J., Erdosi T., et al. Phenotypic and genotypic properties of methicillin resistant strains isolated in Hungary, 1997-2000. Acta Microbiol. Immunol. Hung. 48:2001;457-477
15. Molstad S., Lundborg C.S., Karlsson A.K., et al. Antibiotic prescription rates vary markedly between 13 European countries. Scand. J. Infect. Dis. 34:2002;366-371
16. Stratchounski L., Bedenkov A., Hryniewicz W., et al. The usage of antibiotics in Russia and some countries in Eastern Europe. Int. J. Antimicrob. Agents. 18:2001;283-286
17. Schroeder C.M., Zhao C., DebRoy C., et al. Antimicrobial resistance of Escherichia coli O157 isolated from humans, cattle, swine, and food. Appl. Environ. Microbiol. 68:2001;576-581
18. Alos J.I., Aracil B., Oteo J., et al. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. J. Antimicrob. Chemother. 45:2000;605-609
19. Bassetti M., Manno G., Collida A., et al. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg. Infect. Dis. 6:2000;180-183
20. Cars O., Molstad S., Melander A. Variation in antibiotic use in the European Union. Lancet. 357:2001;1851-1853
21. Jebelean C. Josamycin und Typen der Makrolid-Resistenz bei Streptokokken. Antibiot. Monit. 5:2001;82-85
22. Canton R., Loza E., Morosini M.I. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J. Antimicrob. Chemother. 50:2002;S9-S24
23. Canton R., Loza E., Morosini M.I. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J. Antimicrob. Chemother. 50:2002;9-24